Profit at Uniphar continued to grow at in the first half of the year amid “robust” trading across all its divisions.
The healthcare services provider said gross profit rose 7.7 per cent over the period, with almost 7 per cent of that organic growth.
Revenue was more than €370 million during the six months ended June 30th, a rise of 7.4 per cent.
Earnings before interest, depreciation and amortisation (Ebitda) was 6.2 per cent higher, as the company implemented new strategies in its divisions. Uniphar said that would accelerate in the second half of the year as trading momentum continued.
Adjusted earnings per share grew 11.2 per cent to 10.9 cent.
The board declared an interim dividend of €0.0074 per ordinary share, up 4.2 per cent year on year.
Among the main business units, Uniphar Pharma showed a 7 per cent increase in organic gross profit growth, and remained on track for double digit growth for the year as the business continued to make progress in global sourcing and pharma services.
Uniphar Medtech, meanwhile, showed a 9 per cent rise in organic gross profit growth, while
Uniphar Supply Chain & Retail recorded 5.6 per cent organic gross profit growth.
“Uniphar has delivered a strong first half, with continued organic gross profit growth across the Group. Trading continues to be robust, and the business is developing in line with our expectations,” said Ger Rabbette, Uniphar group chief executive.
“We expect to sustain this progress into the second half and remain on track to meet our growth objectives for each of our three divisions for the full year.”
The group said it was confident of meeting its target of €200 million in ebidta by 2028, with at least 80 per cent of that growth expected to be organic.
It said it is continuing to evaluate potential acquisition opportunities with an active pipeline of opportunities to expand its reach.
Uniphar is facing a full phase-two investigation into its acquisition of TouchStore, which was announced earlier this year, by competition authorities.